Tuesday, June 03, 2008 9:08:39 AM
Monday May 19, 2:08 am ET
MECHELEN, BELGIUM--(MARKET WIRE)--May 19, 2008 --
Mechelen, Belgium, 19 May 2008 - Galapagos NV (Euronext: GLPG) announced today that is has signed a drug discovery research agreement with UCL (University College London). Galapagos' BioFocus DPI service division will perform medicinal chemistry services for a UCL research project. It is also intended that BioFocus DPI will offer UCL ADME[1] screening facilities during the appropriate stages of the work. Total contract value for Galapagos is expected to reach more than EUR 1.8 million over the course of the two-year agreement.
UCL has an ongoing drug discovery program for the treatment of vascular collapse during sepsis (collapsing of blood vessels due to systemic infection by a pathogen). BioFocus DPI will provide medicinal chemistry services to progress UCL's lead series through to pre-clinical testing. In addition UCL will also have the opportunity to utilize BioFocus DPI ADME screening services and will receive access to a selection of compounds in BioFocus DPI's SoftFocus collection to facilitate the identification of new chemical starting points for this drug discovery program.
"We are pleased to add UCL to BioFocus DPI's considerable list of academic partners," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI's leading medicinal chemistry and ADME expertise, such as the newly launched ADME/PK Laboratory, give us a strong edge in winning highly competitive deals."
Recent GLPGF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 08:32:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 09:17:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2024 08:02:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 11:38:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/06/2024 11:00:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/12/2023 12:02:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/12/2023 11:00:11 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/04/2023 10:16:33 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM